ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1620714
This article is part of the Research TopicNew Targets and Strategies for the Prevention and Treatment of Organ Fibrosis, Volume IIIView all 15 articles
Epidemiological Analysis and Temporal Trends of Interstitial Lung Diseases in Global, Chinese, and Belt and Road Initiative Countries: 1990-2021
Provisionally accepted
- 1Zhejiang Chinese Medical University, Hangzhou, China
- 2The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: This study aims to comprehensively evaluate the historical, current, and projected burden of interstitial lung diseases (ILD) across global populations, China, and the Belt and Road Initiative (BRI) countries. Additionally, exploring cross-national inequalities across sociodemographic index (SDI).Methods: From the 2021 Global Burden of Disease (GBD) database, we selected data on interstitial lung diseases (ILD) for global populations, China, and BRI countries. We analyzed the changes in the burden of ILDs according to year, sex, location, age, and SDI, and used the estimated annual percentage change (EAPC) to estimate the trends of the disease burden. Time trends were evaluated using Joinpoint analysis, while health disparities were assessed with the inequality slope index and concentration index. Additionally, the autoregressive integrated moving average (ARIMA) model was employed to forecast the future trends.Results: From 1990 to 2021, the global age-standardized incidence rate (ASIR) of interstitial lung diseases and sarcoidosis (ILD) increased from 3.77 per 100,000 (95% UI: 3.27, 4.28) to 4.55 per 100,000 (95% UI: 4.06, 5.04), with an EAPC of 0.73 (95% CI: 0.63, 0.82). Both the age-standardized mortality rate (ASMR) and the age-standardized disability-adjusted life year (DALY) rate (ASDR) also showed an increase. In 2021, China's ASIR was 2.32 per 100,000 (95% UI 2.03, 2.65), ASMR was 0.39 per 100,000 (95% UI 0.24, 0.53), and ASDR was 10.82 per 100,000 (95% UI 7.70, 13.97). When it comes to rankings among BRI countries, China ranked 49.36% for ASIR, 17.95% for ASMR, and 17.31% for ASDR, from lowest to highest. Countries with higher SDI along the BRI countries had a faster annual average growth rate in ILD incidence, and the inequality in ILD between high SDI and low SDI countries was gradually increasing, albeit to a smaller extent. Predicting the trend of ASDR by 2031, it showed a global downward trend, while it showed an upward trend in Chinese.The ILD burden of BRI countries varies by region, gender, and time factors, and the unbalanced development of their regions exacerbates the imbalance of burden. Therefore, it is necessary to pay attention to and strengthen cooperation in the health field of BRI countries and
Keywords: Belt and road initiative countries, The global burden of disease, Interstitial Lung Disease, Epidemiology, Disability-adjusted life years
Received: 03 May 2025; Accepted: 19 Aug 2025.
Copyright: © 2025 Si, Shi, Ma and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Junchao Yang, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.